Teva Pharmaceutical stocks belong to the fourth quarter income: What happened? -Teva Pharmaceutical INDUS (NYSE: Teva)

Teva Pharmaceutical Industry TEVA On Wednesday, the company’s fourth -quarter financial performance shares fell. This is what you need to know.

What do you know: According to Benzinga Pro’s data, the fourth -quarter revenue reported by TEVA was $ 4.2 billion, defeating analysts’ estimated $ 4.13 billion. The company reports that the income of each share in the fourth quarter is 71 cents, which is estimated to be 70 cents per share.

“Pay attention to the strict implementation of our pivot implementation of the growth strategy throughout the year. We continue to obtain important milestones in each pillar of its four pillars, including beyond our key innovative products. It develops our generic drug business and accelerates our early imitation drugs. Richard FrancisTeva Pharmaceutical President and CEO.

“These results have paved the way for the key tests of Croin’s disease and ulcerative colitis and other immunology and fibrosis adaptives that may cooperate with our partner Sanofi.”

Check it: Danaher Q4: EPS misses the expectations of the diagnosis part.

prospect: Teva Pharmaceutical is expected to revenue between US $ 16.8 billion and US $ 17.4 billion in 2025, and it is estimated to be US $ 17.05 billion. The company is expected to be adjusted from US $ 2.35 to $ 2.65 per share, and it is estimated to be $ 2.79 per share.

“In 2025, we expect our main innovative growth momentum to further progress, and at the same time, with the support of new products, it will also implement our complex generic drugs and biotechnology drug business. We are also glad to be promoted to our Duvakitug ( The third stage test of Anti-TL1A) Assets. “Francis said.

The company’s income guidance seems to be weighing the stock. Management is currently discussing the conference call at 8 am in the United States during the quarter.

Teva price action: According to Benzinga Pro’s data, Teva Pharmaceutical stocks fell 8.78 % to $ 19.64 while publishing.

Photo: provided by Teva Pharmaceutical.